Symbiotec Pharmalab IPO (24-27 August) Analysis

IPO Analysis | BSE and NSE Main Board | 100% Book Built Offer (Fresh Issue and Offer for Sale) | Regulation 6(1)

Based on Red Herring Prospectus dated August 18, 2026 | Corticosteroid and Steroidal-Hormone Active Pharmaceutical Ingredients (APIs) | Indore, Madhya Pradesh

STATUS: LIVE RHP, ANCHOR BID AUGUST 21, BIDDING OPENS AUGUST 24 AND CLOSES AUGUST 27, 2026

Fresh Issue: up to Rs.1,500 Million | Offer for Sale: up to Rs.16,070 Million by Promoter and 2 PE Investor Selling Shareholders | Total Offer up to Rs.17,570 Million | Main Board Listing on BSE and NSE

Global Market Leader with 38.2% Volume Share in Corticosteroid APIs (F&S Report) | RoNW Has Declined Every Year (13.90% to 11.79% to 9.48%) and Trails 3 of 4 Listed Peers

 Symbiotec Pharmalab Limited was incorporated as Symbiotec Pharmalab Private Limited on September 20, 2002, and has converted to a public limited company ahead of this Offer. Its CIN is U24232MP2002PLC015293, with its registered and corporate office in Pigdamber, Rau, Mhow, Indore, Madhya Pradesh. The Promoters are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.

The Company manufactures Active Pharmaceutical Ingredients (APIs), specialising in corticosteroid and steroidal-hormone APIs. Per the F&S Report commissioned for this Offer, the Company holds a 38.2% global volume market share in corticosteroid APIs and 23.8% in steroidal-hormone APIs, and is the only Indian and only global company present across the top 10 corticosteroid and steroidal-hormone APIs as of Fiscal 2026.

Its product portfolio spans over 60 corticosteroid and steroidal-hormone APIs, covering 90% of the addressable market, with market-leading positions in Hydrocortisone (80.1% volume share), Testosterone (76.4%) and Methylprednisolone (76.0%).

The Company operates a vertically integrated 'farm/microbe-to-pharmacy' platform with up to 700 KL of fermentation capacity, holds 43 US FDA DMFs and 23 EDQM CEPs, and serves over 200 customers across more than 40 countries, with an average relationship tenure exceeding 10 years for its top 5 and top 10 customers.

Revenue from operations grew from Rs.7,162.47 million in Fiscal 2024 to Rs.8,691.49 million in Fiscal 2026, while PAT dipped from Rs.1,000.55 million (FY24) to Rs.967.85 million (FY25, down 3.27%) before recovering to Rs.1,099.03 million (FY26, up 13.55%). Despite this recovery, RoNW has declined in every one of the 3 disclosed years (13.90% to 11.79% to 9.48%), a genuine trend discussed in detail in Section 4, and the Company's RoNW trails 3 of its 4 disclosed listed peers.

Key Basics

Particulars	Details
Document Type	Red Herring Prospectus (RHP) dated August 18, 2026. This is a live offer: Anchor Investor Bid Friday, August 21, 2026, Bid or Offer opens Monday, August 24, 2026 and closes Thursday, August 27, 2026.
Issue Structure	100% Book Built Offer comprising a Fresh Issue aggregating up to Rs.1,500.00 million and an Offer for Sale aggregating up to Rs.16,070.00 million by 3 Selling Shareholders, totalling up to Rs.17,570.00 million. Face value Rs.2 per share.
Face Value	Rs.2 per Equity Share.
Selling Shareholders and WACA	Satwani Holdings LLP (Promoter Selling Shareholder, up to Rs.1,440.00 million, WACA Rs.49.43); Rosewood Investments (Investor Selling Shareholder, up to Rs.9,880.00 million, WACA Rs.147.21); India Business Excellence Fund - III (Investor Selling Shareholder, up to Rs.4,750.00 million, WACA Rs.147.21).
Eligibility Route	Regulation 6(1) of the SEBI ICDR Regulations, 2018, the standard main board profitability-based eligibility route.
Listing Exchange	Main board listing on both National Stock Exchange of India (NSE) and BSE Limited; BSE is the Designated Stock Exchange.
BRLMs	A 4-bank syndicate: JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited. Motilal Oswal is disclosed as an associate of Investor Selling Shareholder India Business Excellence Fund - III and will be involved only in marketing the Offer.
Registrar	MUFG Intime India Private Limited (formerly Link Intime India Private Limited).
Bid or Offer Dates	Anchor Bid: Friday, August 21, 2026. Opens: Monday, August 24, 2026. Closes: Thursday, August 27, 2026.
Listed Peers, One Line	4 listed peers in the specialty API and pharma space (Concord Biotech, Divi's Laboratories, Cohance Lifesciences, Laurus Labs); the Company's RoNW is lower than 3 of the 4.

This is a very large, PE-backed main board API manufacturer with a genuinely dominant global market position in its core niche. The Offer for Sale (Rs.16,070.00 million) is overwhelmingly larger than the Fresh Issue (Rs.1,500.00 million), meaning the substantial majority of this Offer represents Promoter and PE investor exits (Rosewood Investments and India Business Excellence Fund - III) rather than new capital into the Company, and one of the 4 BRLMs, Motilal Oswal Investment Advisors, is disclosed as an associate of one of the Investor Selling Shareholders.

How Will the IPO Money Be Used?

Object	Estimated Amount (Rs. Million)	Substantiation
Prepayment and/or repayment, in full or in part, of certain outstanding borrowings	1,125.00	A specific rupee figure disclosed, scheduled for full deployment within FY 2026-27.
General corporate purposes	[TBD]	Capped at 25% of Gross Proceeds. No further breakdown provided, as is standard.

This Issue has no capital expenditure Object: the entire specifically itemised use of the comparatively modest Fresh Issue Net Proceeds is debt repayment, consistent with the Company's disclosed Net Debt position (Rs.3,808.65 million as of FY26).

Notably, the Company's substantial recent capacity investments (2 newly commissioned manufacturing facilities and an expanding Biologics Facility in Ujjain) are not funded by this Offer's Net Proceeds, indicating they have been financed through other means (including the debt this Offer partially repays).

As with all RHPs at this stage, the fund requirements have not been independently appraised, and the Gross Proceeds, Net Proceeds and General Corporate Purposes figures remain undetermined until the Offer Price is fixed.

Financial Performance

P&L and Key Metrics (Rs. Million unless stated)

Particulars	FY 2026	FY 2025	FY 2024
Revenue from operations	8,691.49	7,515.54	7,162.47
Revenue growth (%)	15.65	4.93	26.43
API revenue	8,350.05	7,447.54	7,162.47
CDMO revenue	10.94	68.00	N/A (new segment)
EBITDA	2,319.73	2,061.12	1,770.41
EBITDA margin (%)	26.59	27.26	24.48
Profit after tax	1,099.03	967.85	1,000.55
PAT growth (%)	13.55	(3.27)	N/A
Basic EPS (Rs.)	19.10	17.39	18.00
Net worth	11,586.41	8,211.52	N/A
Net debt	3,808.65	5,179.73	2,430.35
Net debt / EBITDA (times)	1.64	2.51	N/A
Return on net worth / RoNW (%)	9.48	11.79	13.90
NAV per equity share (Rs.)	184.69	150.17	131.79

Independently recomputed, revenue growth decelerated sharply, from 26.43% in FY24 to just 4.93% in FY25, before re-accelerating to 15.65% in FY26. PAT tells an even more textured story: it actually declined 3.27% in FY25 (Rs.1,000.55 million to Rs.967.85 million) before recovering 13.55% in FY26 to Rs.1,099.03 million, meaning FY26 PAT has only just returned to, and modestly exceeded, the FY24 level after a genuine intervening dip. EBITDA margin followed a similar non-linear pattern (24.48% to 27.26% to 26.59%), improving overall but not monotonically.

The most important trend for investors to weigh is RoNW, which has declined in every one of the 3 disclosed years without a single year of improvement: 13.90% (FY24) to 11.79% (FY25) to 9.48% (FY26).

This reflects the Company's Net Worth growing faster than its profit (Net worth rose from an implied lower FY24 base to Rs.8,211.52 million in FY25 to Rs.11,586.41 million in FY26, likely aided by retained earnings and possibly pre-IPO capital activity), a genuine dilution of capital efficiency that is not explained away by a one-off item in the summary reviewed here.

On a more positive note, the Company's Net Debt to EBITDA ratio improved from 2.51 times (FY25) to 1.64 times (FY26), and Net Debt itself fell from Rs.5,179.73 million to Rs.3,808.65 million, indicating genuine, recent deleveraging even as RoNW continued to soften.

How Does It Compare to Peers?

Company	Revenue FY26 (Rs. Million)	Diluted EPS (Rs.)	P/E (times)	RoNW (%)	NAV/Share (Rs.)
Symbiotec Pharmalab Limited	8,691.49	19.00	N/A (Price TBD)	9.48	184.69
Concord Biotech Limited	10,549.00	24.78	61.07	14.00	N/A
Divi's Laboratories Limited	1,05,600.00	96.75	87.80	16.50	631.00
Cohance Lifesciences Limited	22,685.50	4.68	95.02	7.00	N/A
Laurus Labs Limited	68,129.00	16.45	109.36	16.80	N/A

The RHP discloses 4 listed peers in the specialty API and broader pharmaceutical space, Concord Biotech, Divi's Laboratories, Cohance Lifesciences and Laurus Labs, all substantially larger than Symbiotec by revenue (roughly 1.2 to 12.2 times).

Unlike many other companies in this report series, this is a genuinely less favourable peer comparison for Symbiotec on capital efficiency grounds: its FY26 RoNW of 9.48% is lower than 3 of the 4 peers (Concord Biotech 14.00%, Divi's Laboratories 16.50%, Laurus Labs 16.80%), and higher than only Cohance Lifesciences (7.00%).

The industry average P/E across this peer set is a rich 88.32 times (ranging from 61.07 to 109.36 times), reflecting the market's typically high growth and quality premium for specialty API and CDMO businesses; Symbiotec's own P/E cannot yet be calculated pending Offer Price determination.

Key Risks

l RoNW has declined in every one of the 3 disclosed fiscal years (13.90% to 11.79% to 9.48%), and the Company's FY26 RoNW is lower than 3 of its 4 disclosed listed peers; PAT itself declined 3.27% in FY25 before recovering in FY26, meaning the Company's recent capital efficiency and earnings trajectory has been genuinely mixed rather than uniformly improving.

l The Statutory Auditors' examination reports on the Company's Restated Consolidated Summary Statements disclose recurring qualifications across all 3 disclosed fiscal years: a title deed for one leasehold property (carrying value Rs.375.24 million) not held in the Company's name, with registration still pending, and audit trail (edit log) features not fully enabled for certain privileged/administrative access changes in each of FY24, FY25 and FY26. The Company states there was no evidence of tampering where the audit trail was inactive, and that the feature has since been enabled, but the multi-year recurrence of both items is a pattern worth noting.

l The Company has filed a compounding application with the NCLT, Indore (pending as of this RHP) in relation to a historical non-compliance with Section 383A of the Companies Act, 1956, for failing to appoint a whole-time Company Secretary for an extended period, from March 2005 to January 2014 (nearly 9 years), after the Company's paid-up capital crossed the statutory threshold requiring one.

l The overwhelming majority of this Offer (Rs.16,070.00 million of the total Rs.17,570.00 million) is an Offer for Sale by the Promoter Selling Shareholder and 2 PE Investor Selling Shareholders (Rosewood Investments and India Business Excellence Fund - III); the Company itself will receive only the comparatively modest Fresh Issue proceeds (up to Rs.1,500.00 million).

l One of the 4 BRLMs, Motilal Oswal Investment Advisors Limited, is an associate of Investor Selling Shareholder India Business Excellence Fund - III, a disclosed related-party structure within the Offer's own advisory syndicate, though Motilal Oswal's role is limited to marketing under applicable SEBI regulations.

l The Company derives a substantial portion of revenue from certain key customers and exports to various countries, with revenue from the United States alone varying meaningfully year to year (13.12%, 4.02% and 8.97% of revenue in FY26, FY25 and FY24 respectively), indicating some volatility in this specific geographic concentration.

l The Company's manufacturing facilities and dedicated R&D centres are concentrated in Madhya Pradesh, and certain manufacturing facilities are not located on land owned by the Company, held instead on leasehold terms.

l The Company is expanding into new areas, including a Biologics Facility in Ujjain and a recently commenced CDMO business (2025), both of which carry execution and commercialisation risk distinct from the Company's established core API business.

l The Company procures a portion of raw materials from other countries, including China, exposing it to international supply chain and geopolitical risk, and depends on certain suppliers for key raw materials.

l Certain of the Company's corporate records and filings are not traceable or contain discrepancies, spanning multiple historical share allotments and a director appointment, for which the Company has relied on available supporting documentation.

l The Company operates in a highly regulated industry subject to inspections and audits by international regulatory authorities (relevant given its 43 US FDA DMFs and 23 EDQM CEPs), and any adverse finding could affect its ability to supply regulated markets.

l Promoters and certain members of the Promoter Group have encumbered certain Equity Shares of the Company, and some Promoters and Directors may have interests in businesses similar to the Company's own.

Positives to Note

l The Company holds a genuinely dominant, independently verified (F&S Report) global market position: 38.2% volume share in corticosteroid APIs and 23.8% in steroidal-hormone APIs, and is the only Indian and only global company present across the top 10 products in both categories, with market-leading positions exceeding 76% volume share in Hydrocortisone, Testosterone and Methylprednisolone specifically.

l The Company has demonstrated deep, durable customer relationships, with an average relationship tenure exceeding 10 years for both its top 5 and top 10 customers, alongside consistent new customer additions (101, 96 and 89 new customers in FY26, FY25 and FY24 respectively) across a base spanning more than 40 countries.

l The Company holds a substantial, difficult-to-replicate regulatory and technical moat: 43 US FDA DMFs, 23 EDQM CEPs, and differentiated chemistry capabilities supporting up to 400 validated synthesis steps under cGMP, alongside vertical integration covering more than 80% of its product portfolio by revenue.

l Despite the RoNW decline, the Company has genuinely deleveraged in the most recent year, with Net Debt falling from Rs.5,179.73 million to Rs.3,808.65 million and Net Debt to EBITDA improving from 2.51 times to 1.64 times between FY25 and FY26.

l The Company has proactively and specifically disclosed its recurring audit qualifications and the historical Companies Act non-compliance, including the exact remediation steps taken (audit trail enablement dates, the compounding application filed with NCLT Indore) rather than a vague or incomplete disclosure.

l The Company is actively diversifying its growth avenues beyond its core API business, including a newly commenced CDMO segment (2025) and an expanding Biologics Facility, positioning it to capture adjacent growth in complex injectables and biologics manufacturing over time.

Disclaimer

The content on this website is for informational and educational purposes only and should not be construed as investment advice, a recommendation, or a solicitation to buy or sell any security, mutual fund, or financial instrument. Equity Research India is not a SEBI-registered investment advisor or research analyst, and nothing on this site constitutes personalized financial advice.

Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing. Past performance is not indicative of future returns. NAV, returns, rankings, and other data may change and may not reflect the most current information at the time of reading.

Readers should conduct their own due diligence and consult a SEBI-registered financial advisor before making any investment decisions. Equity Research India and its authors accept no liability for any loss or damage arising from the use of this content.